LTR Pharma Logo

LTR Pharma

LTR Pharma is a Clinical Stage Biopharmaceutical Company

SPONTAN® (SDS-089) is a novel intranasal drug (PDE5) delivery platform for Erectile Dysfunction

About Erectile Dysfunction

Erectile Dysfunction (ED) is a condition in which you are unable to get or keep an erection firm enough for satisfactory sexual intercourse. ED can be a short-term or long-term problem.

Our Solution

SPONTAN® provides on demand delivery and faster effect. A lower dose provides less systematic exposure and reduced side effects


LTR Pharma is commercialising a ‘First in Class’ rapid treatment for Erectile Dysfunction (ED) SPONTAN® with fast-track US NDA Filing within two years


worldwide expected cases by 2025


minute effectiveness


projected global market value 2024

Global Market Need

ED is a serious and common medical problem with significant impacts to both physical and psychological health
ED has been identified as a major factor in relationship breakdown (20%). The worldwide prevalence doubled in the last 30 years and is expected to increase to 322 million in 2025.


LTR Pharma Couple



The Courier Mail | LTR hard sell not required

Following last week’s announcement of positive results from our SPONTAN® pivotal bioequivalence clinical study, LTR Pharma was featured in The Courier Mail’s City Beat by business reporter Glen Norris over the weekend. Here’s an excerpt: “LTR, which is developing an intranasal spray treatment called SPONTAN, on Friday released data that

Read More »

SPONTAN® achieves positive clinical study results

LTR Pharma (ASX:LTP) has announced extremely positive results from its SPONTAN® pivotal bioequivalence clinical study. Initial analysis has concluded that SPONTAN® achieves rapid absorption and faster onset of action compared to oral PDE5 inhibitors.  The results demonstrated that SPONTAN achieves rapid absorption and faster onset of action at a substantially

Read More »

Receive our latest news and investor updates

By entering your email address you are agreeing to our privacy policy.